Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Operating Leases: 2020-2023

Historic Operating Leases for Insight Molecular Diagnostics (IMDX) over the last 2 years, with Mar 2023 value amounting to $2.5 million.

  • Insight Molecular Diagnostics' Operating Leases fell 23.33% to $2.5 million in Q1 2023 from the same period last year, while for Mar 2023 it was $2.5 million, marking a year-over-year decrease of 23.33%. This contributed to the annual value of $2.7 million for FY2022, which is 23.02% down from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Operating Leases of $2.5 million as of Q1 2023, which was down 6.56% from $2.7 million recorded in Q4 2022.
  • Insight Molecular Diagnostics' Operating Leases' 5-year high stood at $4.3 million during Q4 2020, with a 5-year trough of $2.5 million in Q1 2023.
  • Its 3-year average for Operating Leases is $3.3 million, with a median of $3.4 million in 2021.
  • Data for Insight Molecular Diagnostics' Operating Leases shows a maximum YoY decreased of 23.33% (in 2023) over the last 5 years.
  • Insight Molecular Diagnostics' Operating Leases (Quarterly) stood at $4.3 million in 2020, then decreased by 17.79% to $3.5 million in 2021, then fell by 23.02% to $2.7 million in 2022, then fell by 23.33% to $2.5 million in 2023.
  • Its Operating Leases was $2.5 million in Q1 2023, compared to $2.7 million in Q4 2022 and $2.9 million in Q3 2022.